Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female

Clin Chim Acta. 2021 Sep:520:71-75. doi: 10.1016/j.cca.2021.05.027. Epub 2021 May 28.

Abstract

Dysbetalipoproteinemia (DBL) is an uncommon condition characterized by a mixed hyperlipidemia due to accumulation of remnant lipoproteins and is highly atherogenic. Typically, DBL is an autosomal recessive condition requiring an additional metabolic stress with reduced apolipoprotein E (apoE) function. However, DBL is also described in patients with multiple myeloma without the characteristic apoE2/E2 mutation seen in familial DBL. Although the underlying pathogenesis in these cases is not fully characterized, it is thought to occur due to interference with apoE function by antibodies produced from clonal plasma cells. Such cases are referred to as hyperlipidemic myeloma (HLM) and have rarely been described in the literature. To our knowledge there is no prior description of HLM in HIV positive patients in Africa. We describe a case of HLM in an African woman with underlying HIV infection who presented with phenotypic and biochemical features of DBL that responded poorly to lipid lowering therapy.

Keywords: Dysbetalipoproteinemia; Hyperlipidemic myeloma; Multiple myeloma; Plasma cell dyscrasia.

Publication types

  • Case Reports

MeSH terms

  • Africa
  • Apolipoprotein E2
  • Apolipoproteins E
  • Female
  • HIV Infections*
  • Humans
  • Hyperlipoproteinemia Type III* / genetics
  • Multiple Myeloma*
  • Triglycerides

Substances

  • Apolipoprotein E2
  • Apolipoproteins E
  • Triglycerides